Positive News SentimentPositive NewsNASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis → The 7th Trillion Dollar Company? (From The Oxford Club) (Ad) Free CRVO Stock Alerts $18.45 -0.24 (-1.28%) (As of 02:42 PM ET) Add Compare Share Share Today's Range$18.11▼$18.7050-Day Range$18.69▼$25.9352-Week Range$4.14▼$26.38Volume13,622 shsAverage Volume25,966 shsMarket Capitalization$113.84 millionP/E RatioN/ADividend YieldN/APrice Target$57.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get CervoMed alerts: Email Address CervoMed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside209.6% Upside$57.50 Price TargetShort InterestHealthy1.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.88Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.13) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector723rd out of 931 stocksPharmaceutical Preparations Industry339th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingCervoMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCervoMed has only been the subject of 1 research reports in the past 90 days.Read more about CervoMed's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.06% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently increased by 101.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVO. Previous Next 3.3 News and Social Media Coverage News SentimentCervoMed has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CervoMed this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CRVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of CervoMed is held by insiders.Percentage Held by InstitutionsOnly 25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CervoMed are expected to decrease in the coming year, from ($1.13) to ($1.62) per share.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 14.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWARNING about the death of the U.S. dollar…Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide. About CervoMed Stock (NASDAQ:CRVO)CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Read More CRVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVO Stock News HeadlinesMay 20, 2024 | markets.businessinsider.comCervoMed Appoints William Elder To Succeed William Tanner As CFOMay 20, 2024 | globenewswire.comCervoMed to Appoint William Elder as Chief Financial OfficerMay 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)May 15, 2024 | msn.comCRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024May 15, 2024 | globenewswire.comCervoMed Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesApril 19, 2024 | wsj.comCervoMed Inc.April 15, 2024 | benzinga.comCRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24April 10, 2024 | uk.investing.comCervoMed shares target raised by Canaccord on positive trial outlookApril 10, 2024 | finance.yahoo.comCRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…April 3, 2024 | seekingalpha.comCervoMed: H2 2024 Data For DLB Program A Major Inflection PointApril 1, 2024 | globenewswire.comCervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 30, 2024 | uk.investing.comCervoMed secures $50 million in private placementMarch 28, 2024 | globenewswire.comCervoMed to Participate in Upcoming Investor ConferencesMarch 28, 2024 | globenewswire.comCervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare InvestorsMarch 9, 2024 | finance.yahoo.comCervoMed Inc.'s (NASDAQ:CRVO): Top Key Executive Sylvie Gregoire is the most bullish insider, and their stock value gained 29% last weekMarch 7, 2024 | uk.investing.comCervoMed reports promising dementia treatment trial resultsMarch 5, 2024 | globenewswire.comCervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024February 25, 2024 | msn.comCervoMed (CRVO) Price Target Increased by 97.06% to 34.17February 21, 2024 | finance.yahoo.comCervoMed to Participate in the BIO CEO and Investor ConferenceFebruary 21, 2024 | globenewswire.comCervoMed to Participate in the BIO CEO and Investor ConferenceFebruary 12, 2024 | finance.yahoo.comCervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy BodiesFebruary 9, 2024 | proactiveinvestors.comCervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the BoardFebruary 8, 2024 | msn.comCervoMed Appoints New Chair and Presents at Conference 67February 8, 2024 | msn.comCervoMed Names Joshua Boger as New Board ChairFebruary 7, 2024 | finance.yahoo.comCervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the BoardSee More Headlines Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/28/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CUSIPN/A CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$57.50 High Stock Price Target$65.00 Low Stock Price Target$50.00 Potential Upside/Downside+207.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,170,000.00 Net MarginsN/A Pretax Margin-51.35% Return on Equity-45.48% Return on Assets-36.34% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual Sales$7.14 million Price / Sales16.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book14.38Miscellaneous Outstanding Shares6,170,000Free Float6,047,000Market Cap$115.38 million OptionableNot Optionable Beta1.50 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. John J. Alam M.D. (Age 62)Co-Founder, CEO, President & Director Comp: $680.25kDr. Sylvie L. Gregoire Pharm.D. (Age 63)Co-Founder & Director Comp: $352.43kMr. William Robert Elder J.D. (Age 41)General Counsel, Corporate Secretary & Acting Principal Financial Officer Comp: $407.55kDr. Robert J. Cobuzzi Jr. (Age 59)Ph.D., COO & Director Comp: $386.6kMs. Kelly Blackburn M.H.A. (Age 60)Senior Vice President of Clinical Development Comp: $404.94kDr. John William Tanner Ph.D. (Age 65)Chief Financial Officer (Leave of Absence) More ExecutivesKey CompetitorsAnnexonNASDAQ:ANNXErascaNASDAQ:ERASKorro BioNASDAQ:KRROLarimar TherapeuticsNASDAQ:LRMRFulcrum TherapeuticsNASDAQ:FULCView All CompetitorsInstitutional OwnershipRA Capital Management L.P.Bought 861,573 shares on 5/17/2024Ownership: 13.964%Ikarian Capital LLCBought 237,345 shares on 5/17/2024Ownership: 3.847%Crown Advisors Management Inc.Bought 100,000 shares on 5/10/2024Ownership: 1.621%View All Institutional Transactions CRVO Stock Analysis - Frequently Asked Questions Should I buy or sell CervoMed stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CervoMed in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRVO shares. View CRVO analyst ratings or view top-rated stocks. What is CervoMed's stock price target for 2024? 2 equities research analysts have issued 12 month target prices for CervoMed's shares. Their CRVO share price targets range from $50.00 to $65.00. On average, they anticipate the company's stock price to reach $57.50 in the next twelve months. This suggests a possible upside of 209.6% from the stock's current price. View analysts price targets for CRVO or view top-rated stocks among Wall Street analysts. How have CRVO shares performed in 2024? CervoMed's stock was trading at $7.63 at the beginning of 2024. Since then, CRVO shares have increased by 143.4% and is now trading at $18.57. View the best growth stocks for 2024 here. When is CervoMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CRVO earnings forecast. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) issued its earnings results on Tuesday, May, 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.05. The company earned $2.35 million during the quarter, compared to analyst estimates of $2 million. Who are CervoMed's major shareholders? CervoMed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (13.96%), Ikarian Capital LLC (3.85%) and Crown Advisors Management Inc. (1.62%). How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRVO) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThe 7th Trillion Dollar Company?The Oxford ClubThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesWARNING about the death of the U.S. dollar…Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
